Literature DB >> 11965396

Structure-based screening and design in drug discovery.

Maria van Dongen1, Johan Weigelt, Jonas Uppenberg, Johan Schultz, Mats Wikström.   

Abstract

Structure-based screening represents an integrated approach for the identification and optimization of hits by the combined use of nuclear magnetic resonance (NMR) spectroscopy, homology modeling and X-ray crystallography. A general feature of the methodology is the introduction of structure-based methods (NMR, modeling and X-ray) early in the drug discovery process to optimize hits in terms of their affinities and specificities. This approach promises to deliver leads with improved physicochemical properties as compared with leads generated from a traditional HTS program. This review presents examples of structure-based screening from published and in-house drug discovery projects.

Mesh:

Substances:

Year:  2002        PMID: 11965396     DOI: 10.1016/s1359-6446(02)02233-x

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  6 in total

1.  A 3D doubly sensitivity enhanced X-filtered TOCSY-TOCSY experiment.

Authors:  Hugo van Ingen; Marco Tessari; Geerten W Vuister
Journal:  J Biomol NMR       Date:  2002-10       Impact factor: 2.835

Review 2.  The role of small-angle scattering in structure-based screening applications.

Authors:  Po-Chia Chen; Janosch Hennig
Journal:  Biophys Rev       Date:  2018-10-10

3.  Auto-FACE: an NMR based binding site mapping program for fast chemical exchange protein-ligand systems.

Authors:  Janarthanan Krishnamoorthy; Victor C K Yu; Yu-Keung Mok
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

Review 4.  High-field solution NMR spectroscopy as a tool for assessing protein interactions with small molecule ligands.

Authors:  Andria L Skinner; Jennifer S Laurence
Journal:  J Pharm Sci       Date:  2008-11       Impact factor: 3.534

5.  An NMR-based scoring function improves the accuracy of binding pose predictions by docking by two orders of magnitude.

Authors:  Julien Orts; Stefan Bartoschek; Christian Griesinger; Peter Monecke; Teresa Carlomagno
Journal:  J Biomol NMR       Date:  2011-12-14       Impact factor: 2.835

Review 6.  Ace revisited: a new target for structure-based drug design.

Authors:  K Ravi Acharya; Edward D Sturrock; James F Riordan; Mario R W Ehlers
Journal:  Nat Rev Drug Discov       Date:  2003-11       Impact factor: 84.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.